Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · September 18, 2024

Safety and Efficacy of the Novel Incretin Co-Agonist Cotadutide in Patients With Biopsy-Proven Noncirrhotic MASH With Fibrosis

Clinical Gastroenterology and Hepatology

 

Additional Info

Clinical Gastroenterology and Hepatology
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
Clin. Gastroenterol. Hepatol. 2024 Sep 01;22(9)1847-1857.e11, SS Shankar, SJ Daniels, D Robertson, J Sarv, J Sánchez, D Carter, L Jermutus, B Challis, AJ Sanyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading